Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

DUR COMMITTEE AGENDA

Date: Tuesday, June 16, 2020
Time: 6:00PM to 8:30PM
Location: Virtual: Join Zoom Meeting
https://us02web.zoom.us/j/81527261365?pwd=VTZLdVVtMEZSVmFYZy85NXo2MzIzUT09
Meeting ID: 815 2726 1365
Password: 5wXuTD

1) Closed Session: 5:30PM- 6:00PM- Board members only (a separate invitation to be sent)
2) MaineCare Updates
3) Public Comments
4) Old Business
   - Approve March Meeting Minutes
   - Intranasal Ketamine
5) Revised clinical criteria
   - Biosimilars
     - Ontruzant (Herceptin)
     - Trazimera (Herceptin)
6) New Business (open session)
   - Retro DUR
     - Data Presentation: Prescriber PDL Compliance (pick 6 categories)
     - Introduce: Prep HIV therapy prescribing rates
   - New Drug Review

Annovera	Koselugo	Trijardy XR
Arazlo Lotion	Nexletol	Tukysa
Caplyta	Nurtec	Valtoco
Dayvigo	Palforzia	Vyepti
Fetroja	Pemazyre	Xepi
Isturisa	Sarclisa	Zerviate
Jatenzo	Talicia	

7) FDA Safety Alerts

Clozaril, Fazaclo ODT, Versacloz (clozapine): Drug Safety Communication - FDA Strengthens Warning That Untreated Constipation Can Lead to Serious Bowel Problems
https://www.fda.gov/safety/medical-product-safety-information/clozaril-fazaclo-odt-versacloz-clozapine-drug-safety-communication-fda-strengthens-warning-untreated?utm_campaign=FDA%20MedWatch%3AClozaril%2C%20Fazaclo%20ODT%2C%20Versacloz%20%28clozapine%29-%20Drug%20Safety%20Communication&utm_medium=email&utm_source=Eloqua

FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process
https://www.fda.gov/news-events/press-announcements/fda-approves-three-drugs-nonprescription-use-through-rx-otc-switch-process?utm_campaign=022420_PR_FDA%20Approves%20Three%20Drugs%20for%20Nonprescription%20Use&utm_medium=email&utm_source=Eloqua

Singulair (montelukast) and All Montelukast Generics: Strengthened Boxed Warning - Due to Restricting Use for Allergic Rhinitis
https://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use?utm_campaign=FDA%20MedWatch%20Singulair%20%28montelukast%29%3A%20Strengthened%20Boxed%20Warning&utm_medium=email&utm_source=Eloqua

FDA Approves Label Changes to SGLT2 Inhibitors Regarding Temporary Discontinuation of Medication Before Scheduled Surgery
http://s2027422842.t.en25.com/e/es?s=2027422842&e=312214&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=d700e2d071b343878fdae02a4ebbbf19&elqaid=11643&elqat=1

FDA alerts patients and health care professionals of EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injector errors related to device malfunctions and user administration
https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-and-health-care-professionals-epipen-auto-injector-errors-related-device?utm_campaign=FDA%20alerts%20patients%20and%20health%20care%20professionals%20of%20EpiPen%20auto-injector%20errors&utm_medium=email&utm_source=Eloqua
FDA Requests Removal of All Ranitidine Products (Zantac) from the Market
https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market?utm_campaign=040120_PR_FDA%20Requests%20Removal%20of%20Ranitidine%20Products%20%28Zantac%29%20from%20the%20Market&utm_medium=email&utm_source=Eloqua
FDA Approves Label Changes for Montelukast (Singulair) Regarding the Potential Risk of Serious Mental Health Side Effects
http://s2027422842.t.en25.com/e/es?s=2027422842&e=328327&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=bb3dd6d269764f269f7b497fd4704f1b&elqaid=12344&elqat=1
FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems
http://s2027422842.t.en25.com/e/es?s=2027422842&e=326625&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=ac707a3bff784a399dcd62181c0aa736&elqaid=12264&elqat=1

8) Next Meeting (Tuesday, September 8, 2020 (from 5:30pm to 8:30pm)
9) Adjournment: 8:30PM